-
公开(公告)号：US10959992B2
公开(公告)日：2021-03-30
申请号：US16943426
申请日：2020-07-30
申请人： Bridge Pharma, Inc.
IPC分类号： A61K31/4465 , A61K9/00 , A61P11/06 , A61K45/06
摘要： Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.
-
公开(公告)号：US20210186945A1
公开(公告)日：2021-06-24
申请号：US17177888
申请日：2021-02-17
申请人： Bridge Pharma, Inc.
IPC分类号： A61K31/4465 , A61K9/00 , A61P11/06
摘要： Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.
-
公开(公告)号：US20200268734A1
公开(公告)日：2020-08-27
申请号：US16751539
申请日：2020-01-24
申请人： Bridge Pharma, Inc.
摘要： Described herein are methods of administering the anti-inflammatory drug norketotifen, an isomer, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorder such as asthma and COPD in a human patient in need of such treatment, without exposing said patient to adverse immune-suppression. Dosage regimens for oral administration including a loading dosage followed by a maintenance dosage are described. Also described are methods and conditions wherein norketotifen is administered by oral inhalation. Yet, further included are methods of administering norketotifen directly to the nasal passages of the human patients in need thereof, in order to reduce or eliminate inflammatory symptoms of airways disorders, such as sinusitis, laryngitis, nasopharyngitis and various forms of rhinitis.
-
公开(公告)号：US20230000852A1
公开(公告)日：2023-01-05
申请号：US17851165
申请日：2022-06-28
申请人： Bridge Pharma, Inc.
发明人： A.K. Gunnar Aberg , Kresimir Pucaj
IPC分类号： A61K31/4535 , A61P29/00
摘要： Described herein are methods of treating human and canine patients suffering from dermal Cytokine Storm syndromes related to dermal diseases such as atopic dermatitis, psoriasis or urticaria. A method of reducing the incidence and/or the intensity of a symptom of dermal hypercytokinemia in a patient suffering from an underlying dermal condition who develops the dermal hypercytokinemia as a consequence of the underlying dermal condition includes administering to the patient a therapeutically effective amount of norketotifen an isomer, an isomeric mixture, a prodrug or a pharmaceutically acceptable salt thereof. The symptom of dermal hypercytokinemia is an eruption of new dermal lesions accompanied by intense lesional and/or non-lesional pruritus.
-
公开(公告)号：US11197851B2
公开(公告)日：2021-12-14
申请号：US17177888
申请日：2021-02-17
申请人： Bridge Pharma, Inc.
IPC分类号： A61K31/4465 , A61K9/00 , A61P11/06 , A61K45/06
摘要： Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.
-
公开(公告)号：US20210267960A1
公开(公告)日：2021-09-02
申请号：US17185034
申请日：2021-02-25
申请人： Bridge Pharma Inc.
IPC分类号： A61K31/4535 , A61K39/395 , A61K31/519 , A61K45/06 , A61K9/00 , A61K9/20
摘要： Methods of treating a patient suffering from a TNFα associated arthritic disorder with the cytokine release inhibitor norketotifen include orally or topically administering to the subject in need thereof a therapeutically effective amount of norketotifen, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof. Also included are methods of intra-articular injection of norketotifen, such as into a joint of a subject in need thereof.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.046 秒)
